Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 25
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Clinical, cognitive, and neuroimaging evidence of a neurodevelopmental continuum in offspring of probands with schizophrenia and bipolar disorder

  • Sugranyes, Gisela
  • Serna, Elena de la
  • Borras, Roger
  • Sanchez Gistau, Vanessa
  • Pariente, Jose C.
  • Romero, Soledad
  • Baeza, Inmaculada
  • Martínez Díaz-Caneja, María Covadonga
  • Rodríguez Toscano, Elisa
  • Moreno Ruiz, María del Carmen
  • Bernardo, Miguel
  • Moreno Pardillo, Dolores María
  • Vieta, Eduard
  • Castro Fornieles, Josefina
Background: Studies in child and adolescent offspring of patients with schizophrenia or bipolar disorders may help understand the influence of neurodevelopmental factors on the premorbid phenotype of these disorders. Aims: To assess whether a combination of neurodevelopmental factors discriminates between young offspring of patients with schizophrenia (SzO) or bipolar disorder (BpO) and community controls (CcO). To assess the association between these factors and rates of psychiatric diagnoses in high risk (HR) youth. Methods: One hundred thirty-three HR offspring (47 SzO and 86 BpO) and 84 CcO, aged 6–17, underwent cross-sectional clinical, neurocognitive, and structural neuroimaging assessment. Information on perinatal events and early childhood development was also obtained. General linear mixed models were performed to assess group discrimination and association with lifetime axis I psychiatric disorders. Results: Multivariate analyses revealed that greater neurological soft signs (NSS), less total grey matter volume (GMV) and a higher frequency of obstetric complications discriminated HR offspring from CcO. When comparing each group individually, greater NSS and a higher frequency of obstetric complications discriminated SzO from CcO, and BpO from CcO, while lower intelligence also discriminated SzO from CcO and from BpO. Within HR offspring, lower intelligence and less total GMV were associated with lifetime incidence of psychiatric disorders. Conclusions: Both SzO and BpO showed evidence of neurodevelopmental insult, although this may have a greater impact in SzO. Lower intelligence and less total GMV hold potential as biomarkers of risk for psychiatric disorders in HR youth.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

La psiquiatría post-COVID-19

  • Vieta, Eduard
  • Pérez Solà, Víctor
  • Arango, Celso
EV would like to thank the Ministry of Science and Research (PI15/00283, PI18/00805) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), the Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 1365), and project SLT006/17/00357 of the Strategic Plan for Health Research and Innovation (PERIS) 2016–2020 (Department of Health), CERCA PROGRAM, Government of Catalonia. VP would like to thank the Ministry of Science and Research (PI19/00236) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), CIBERSAM G21. Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 134), CERCA Program, Government of Catalonia. CA has received support from the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by the European Commission's ERDF Fund, “A way of making Europe,” CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 115916, Project PRISM, and grant agreement No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, and Fundación Alicia Koplowitz.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The role of premorbid IQ and age of onset as useful predictors of clinical, functional outcomes, and recovery of individuals with a first episode of psychosis

  • Molina-García, Mariola
  • Fraguas, David
  • Rey-Mejías, Ángel del
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Inmaculada
  • Mané, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo, Miguel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, 'A way of making Europe', CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTi-MISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González Pinto, Ana
  • González-Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo, Miguel
  • Bioque, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez Torres, Ana María
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis., The Spanish Ministry of Economy and Competitiveness (Ref. ISCIII 2009-2011:PI 080208), the Instituto de Salud Carlos III-European Fund for Regional Development (PI10/01430, PI10/01746, PI11/01977, PI11/02708, 2011/1064, PI12/02077, PI13/02252, PI13/00451 and PI14/01900, PI11/02831), the Centre for Biomedical Research in the Mental Health Network (CIBERSAM), the Health Department of the Government of Navarre (11/101 and 87/2014), the Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2014SGR441), the Contract FI-DGR-2013 from the Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR (2015 FI_B2 00100 to GM), the Esther Koplowitz Centre (Barcelona), local grants from the Department of Education, Linguistic Policy and Culture of the Basque Country Government, the Basque Foundation for Health Innovation and Research (BIOEF), Madrid Regional Government (S2010/BMD-2422 AGES), European Union Structural Funds and European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); Alicia Koplowitz Foundation, Mutua Madrileña Foundation and the University of the Basque Country (GIC10/80, GIC12/84). The psychiatric research department at Araba University Hospital is supported by the Stanley Research Foundation (03-RC-003).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejías, Ángel
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto Arrillaga, Ana María
  • Andreu Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Immaculada
  • Mané, Anna
  • Cuesta, Manuel
  • de la Serna, Elena
  • Payá, Beatriz
  • Zorrilla Martínez, Iñaki
  • Arango, Celso
  • Bernardo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l’any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l’atenció primària, amb el codi d’expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz Caneja, Covadonga
  • Costas, Javier
  • de Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás, Lourdes
  • Bobes, Julio
  • González Pinto Arrillaga, Ana María
  • Crespo Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, María Dolores
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango, Celso
  • González Peñas, Javier
[EN] Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N=3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. We are grateful to Paloma Pantoja for her assistance in the design of the figures. A.A.-B. holds a Rio Hortega Grant from Instituto de Salud Carlos III (CM20/00114). C.M.D.-C. holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, Ana
  • González Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo Arroyo, Miquel
  • Bioque Alcázar, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez-Torres, Ana M.
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psycho- sis sample, when stratifying the interaction by cannabis use and familial or non-familial psy- chosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family his- tory of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no fam- ily history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • De Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás Saura, Lourdes
  • Bobes García, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, M. Dolors
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango López, Celso
  • González-Peñas, Javier
Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N = 3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets

  • Postema, Merel C.
  • van Rooij, Daan
  • Anagnostou, Evdokia
  • Arango, Celso
  • Auzias, Guillaume
  • Behrmann, Marlene
  • Filho, Geraldo Busatto
  • Calderoni, Sara
  • Calvo Escalona, Rosa
  • Daly, Eileen
  • Deruelle, Christine
  • Di Martino, Adriana
  • Dinstein, Illan
  • Duran, Fabio Luis S.
  • Durston, Sarah
  • Ecker, Christine
  • Ehrlich, Stefan
  • Fair, Damien
  • Fedor, Jennifer
  • Feng, Xin
  • FitzGerald, Jackie
  • Floris, Dorothea L.
  • Freitag, Christine M.
  • Gallagher, Louise
  • Glahn, David C.
  • Gori, Ilaria
  • Haar, Shlomi
  • Hoekstra, Liesbeth
  • Jahanshad, Neda
  • Jalbrzikowski, Maria
  • Janssen, Joost
  • King, Joseph A.
  • Kong, Xiang-Zhen
  • Lázaro García, Luisa
  • Lerch, Jason P.
  • Luna, Beatriz
  • Martinho, Mauricio M.
  • McGrath, Jane
  • Medland, Sarah E.
  • Muratori, Filippo
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejias, Angel
  • Mezquida Mateos, Gisela
  • Sánchez-Torres, Ana M.
  • Amoretti Guadall, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta i Pascual, Eduard, 1963-
  • Baeza, Inmaculada, 1970-
  • Mané Santacana, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la, 1978-
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo Arroyo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

  • Sideli, Lucia
  • Schimmenti, Adriano
  • La Barbera, Daniele
  • La Cascia, Caterina
  • Ferraro, Laura
  • Aas, Monica
  • Alameda, Luis
  • Velthorst, Eva
  • Fisher, Helen L.
  • Caretti, Vincenzo
  • Trotta, Giulia
  • Tripoli, Giada
  • Quattrone, Diego
  • Gayer-Anderson, Charlotte
  • Seminerio, Fabio
  • Sartorio, Crocettarachele
  • Marrazzo, Giovanna
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Berardi, Domenico
  • D'Andrea, Giuseppe
  • Arango, Celso
  • Arrojo, Manuel
  • Bernardo, Miguel
  • Bobes, Julio
  • Sanjuán, Julio
  • Santos, José Luis
  • Menezes, Paulo Rossi
  • Del-Ben, Cristina Marta
  • Jongsma, Hannah E.
  • Jones, Peter B.
  • Kirkbride, James B.
  • Llorca, Pierre-Michel
  • Tortelli, Andrea
  • Pignon, Baptiste
  • de Haan, Lieuwe
  • Selten, Jean-Paul
  • Van Os, Jim
  • Rutten, Bart P. F.
  • Di Forti, Marta
  • Morgan, Craig
  • Murray, Robin M.
[Background and hypothesis] Evidence suggests that childhood maltreatment (ie, childhood abuse and childhood neglect) affects educational attainment and cognition. However, the association between childhood maltreatment and Intelligence Quotient (IQ) seems stronger among controls compared to people with psychosis. We hypothesised that: the association between childhood maltreatment and poor cognition would be stronger among community controls than among people with first-episode of psychosis (FEP); compared to abuse, neglect would show stronger associations with educational attainment and cognition; the association between childhood maltreatment and IQ would be partially accounted for by other risk factors; and the association between childhood maltreatment, educational attainment, and IQ would be stronger among patients with affective psychoses compared to those with nonaffective psychoses., [Study Design] 829 patients with FEP and 1283 community controls from 16 EU-GEI sites were assessed for child maltreatment, education attainment, and IQ., [Study Results] In both the FEP and control group, childhood maltreatment was associated with lower educational attainment. The association between childhood maltreatment and lower IQ was robust to adjustment for confounders only among controls. Whereas childhood neglect was consistently associated with lower attainment and IQ in both groups, childhood abuse was associated with IQ only in controls. Among both patients with affective and nonaffective psychoses, negative associations between childhood maltreatment and educational attainment were observed, but the crude association with IQ was only evident in affective psychoses., [Conclusions] Our findings underscore the role of childhood maltreatment in shaping academic outcomes and cognition of people with FEP as well as controls., The EU-GEI Study is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417-0 from the São Paulo Research Foundation. B.P.F. Rutten is funded by a VIDI award (no. 91.718.336) from the Netherlands Scientific Organization. H. L. Fisher, C. Gayer-Anderson, and C. Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King’s College London [ES/S012567/1]. C. Arango has received support by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements, FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. J.B. Kirkbride is supported by the NIHR University College London Hospital Biomedical Research Centre., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-analysis

  • Barth, Claudia
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
et al., Emerging evidence suggests brain white matter alterations in adolescents with early-onset psychosis (EOP; age of onset <18 years). However, as neuroimaging methods vary and sample sizes are modest, results remain inconclusive. Using harmonized data processing protocols and a mega-analytic approach, we compared white matter microstructure in EOP and healthy controls using diffusion tensor imaging (DTI). Our sample included 321 adolescents with EOP (median age = 16.6 years, interquartile range (IQR) = 2.14, 46.4% females) and 265 adolescent healthy controls (median age = 16.2 years, IQR = 2.43, 57.7% females) pooled from nine sites. All sites extracted mean fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD) for 25 white matter regions of interest per participant. ComBat harmonization was performed for all DTI measures to adjust for scanner differences. Multiple linear regression models were fitted to investigate case-control differences and associations with clinical variables in regional DTI measures. We found widespread lower FA in EOP compared to healthy controls, with the largest effect sizes in the superior longitudinal fasciculus (Cohen’s d = 0.37), posterior corona radiata (d = 0.32), and superior fronto‐occipital fasciculus (d = 0.31). We also found widespread higher RD and more localized higher MD and AD. We detected significant effects of diagnostic subgroup, sex, and duration of illness, but not medication status. Using the largest EOP DTI sample to date, our findings suggest a profile of widespread white matter microstructure alterations in adolescents with EOP, most prominently in male individuals with early-onset schizophrenia and individuals with a shorter duration of illness., ENIGMA Core: U.S. National Institutes of Health grants, R01 EB015611, U54 EB020403, R01 MH116147, R01 MH117601, R01 MH121246, S10 OD023696. YTOP: The Research Council of Norway (223273, 2137000, 250358, 288083); South-Eastern Norway Regional Health Authority (2017112, 2022080); KG Jebsen Stiftelsen (SKGJ-MED-008). MADRID: Celso Arango has received funding from CIBERSAM: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, co-financed by ERDF Funds from the European Commission, “A way of making Europe”; CIBERSAM; Instituto de Investigación Sanitaria Gregorio Marañón; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2, Youth Employment Operational Program and Youth Employment Initiative); European Social Fund and EU Structural Funds; EU Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2009-2.2.1-3-242114, FP7-HEALTH-2013-2.2.1-2-602478, and FP7-HEALTH-2013-2.2.1-2-603196; EU H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. Covadonga M. Díaz-Cenaj has received grant support from Instituto de Salud Carlos III (PI17/00481, PI20/00721, JR19/00024). FEMS: This project was supported by an unrestricted grant from AstraZeneca. Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and APP1156072). SCAPS: The Swedish Research Council (521-2014-3487, 2017-00949); FORMAS (259-2012-31). OXFORD: MRC G0500092. PAFIP: This study was supported by grants from Carlos III Health Institute (IPI17/00402, PI17/01056, PI14/00639 and PI14/00918) cofunded by The European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. BARCELONA: Inmaculada Baeza has received research funds from the Spanish Ministry of Health, Instituto de Salud Carlos II, supported by ERDF Funds from the European Comission (PI18/0242 and PI21/0391), “Otra manera de hacer Europa”, and Fundación Alcia Koplowitz. Elena de la Serna has received grant support from Instituto de Salud Carlos III (PI20/00654). Gisela Sugranyes has received research funds from Instituto de Salud Carlos III (PI1800976 and PI2100330), the Alicia Koplowitz Foundation (AKOPLOWITZ20_004), Ajut a la Recerca Pons Bartran (FCRB_PB1_2018) and a Brain and Behaviour Research Foundation NARSAD 2017 Young Investigator Grant (26731). UCLA: NIMH grants U01MH081902, P50MH066286., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

  • Constantinides, Constantinos
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Walton, Esther
C. Constantinides et al., Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18-72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18-73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen's d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions., The ENIGMA Schizophrenia Working Group acknowledges the National Institutes of Health (NIH) Big Data to Knowledge (BD2K) award for foundational support and consortium development (Grant No. U54 EB020403 to PMT). CC was supported by grant MR/N0137941/1 for the GW4 BIOMED Doctoral Training Partnership awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/ UK Research & Innovation (UKRI). JHC was supported by a UKRI Innovation Fellowship (MR/R024790/2). LE was supported by Desert-Pacific Mental Illness Research Education and Clinical Center, US, NIH grant R01MH083968-05. TH was funded by the German Research Foundation (DFG grants HA7070/2-2, HA7070/3, HA7070/4 to TH). LH was supported by a Rubicon fellowship (grant number 452020227) provided by The Dutch Research Council (NWO). NJ and LS were supported by NIH grant R01 MH117601. NJ was also supported by NIH grants R01AG059874, R01MH11760. LS was also supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship (1140764) and a University of Melbourne Dame Kate Campbell fellowship. PMT was supported in part by NIH grant R01 MH116147. EW was supported by the European Union Horizon 2020 research and innovation programme (EarlyCause, grant number 848158). Acknowledgements for the various participating data contributors follow - ASRB: the Australian Schizophrenia Research Bank (ASRB) was supported by NHMRC (Enabling Grant, ID 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. CP was also supported by a NHMRC Senior Principal Research Fellowship (1105825), an NHMRC L3 Investigator Grant (1196508). CSW was funded by the NSW Ministry of Health, Office of Health and Medical Research and a recipient of a National Health and Medical Research Council (Australia) Principal Research Fellowship (PRF) (#1117079). CAMH: the datasets were generated and shared with support from the CAMH Foundation and the Canadian Institutes of Health Research. CASSI: this study was supported by NHMRC grant 568807 (awarded to CSW and TW). CSW was funded by the NSW Ministry of Health, Office of Health and Medical Research and a recipient of a NHMRC (Australia) Principal Research Fellowship (PRF) (#1117079). COBRE: the study and investigators were supported by NIH grants R01MH118695, R01MH121101, as well as National Science Foundation (NSF) grant 2112455 (awarded to VC). JT (senior author) was supported by NIH grant R01MH121246. EONCKS: all processing of contributed neuroimaging data was conducted on the Centre for High Performance Computing, Cape Town, South Africa. ESO: the study and investigators (AC, FS, DT) was funded by the Ministry of Health, Czech Republic - Conceptual Development of Research Organization (Institute for Clinical and Experimental Medicine – IKEM, IN 00023001), and Ministry of Health of the Czech Republic, grants nr. NU20-04-00393 and NU21-08-00432. FBIRN: The study was supported by National Institutes of Health grant numbers: NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network), NIH 1 U24 RR025736 (Biomedical Informatics Research Network Coordinating). FBIRN data was processed by the UCI High Performance Computing cluster supported by Joseph Farran, Harry Mangalam, and Adam Brenner and the NCRR and the National Center for Advancing Translational Sciences. JT (senior author) was also supported by NIH grant R01MH121246. FIDMAG: this study was supported by Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and the Catalonian Government, Generalitat de Catalunya (2017-SGR-1271 to EP-C from AGAUR). PFC was supported by a Sara Borrell contract (CD19/00149), funded by Instituto de Salud Carlos III, co-funded by the European Union (European Regional Development Fund/European Social Fund [ERDF/ESF], “Investing in your future”). FSLRome: the IRCCS Santa Lucia Foundation of Rome study (FSLRome) was partially supported by the Italian Ministry of Health (RC12-13-14-15A Grant) and by the European Commission ERA-Net NEURON joint transnational calI 2010 (European Research Projects on Mental Disorders: NEUCONNECT). GROUP: This work was supported by the Geestkracht program of the Dutch Health Research Council (ZON-MW, grant number: 10-000-1002), and the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Huilong: this study was funded by the National Natural Science Foundation of China (81761128021;31671145;81401115;81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016) and Beijing Natural Science Foundation (7162087, Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: The Imaging Genetics in Psychosis (IGP) study was supported by NHMRC Project Grant APP630471, APP1051673, APP1081603 (awarded to MJG), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). MJG was supported by an Australian Research Council Future Fellowship (FT0991511; 2009-13) and a R.D. Wright Biomedical Career Development Award from the NHMRC (1061875; 2014-17). IMH: this study was supported by the National Healthcare Group, Singapore (SIG/05004; SIG/05028) and the Singapore Bioimaging Consortium (RP C009/06) research grants (awarded to KS). iRELATE: this study was supported by grants to GD from the European Research Council (ERC-2015-STG-677467) and Science Foundation Ireland (SFI-16/ERCS/3787). JBNU: YC was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HI18C2383). Madrid: this research was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (grants SAM16PE07CP1, PI16/02012, and PI19/01024 awarded to CAra; PI17/01249 awarded JJ; and PI17/00481, JR19/00024 and PI20/00721 awarded to CMD-C), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2 awarded to CAra), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY) awarded to Cara; and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS awarded to CAra), Fundación Familia Alonso and Fundación Alicia Koplowitz. MCIC: this work was primarily supported by the Department of Energy (DE-FG02- 99ER62764) and the Mind Research Network. VC was also supported by NSF (grant no. 2112455) and NIH (grant no. R01MH118695, R01MH121101). MPRC: support was received from NIH grants R01MH123163, R01EB015611, R01NS114628 (awarded to PK). PAFIP: this study has been funded by Instituto de Salud Carlos III through the project PI17/01056 (co-funded by ERDF/ESF “A way to make Europe”/“Investing in your future”). RSCZ: the study was supported by National Institutes of Health grant number: NIMH R21MH097196 to TGMvE. SCORE: this study was supported in part by grant 3232BO_119382 from the Swiss National Science Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

  • Schijven, Dick
  • Postema, Merel C.
  • Fukunaga, Masaki
  • Tordesillas-Gutiérrez, Diana
  • Crespo-Facorro, Benedicto
  • Francks, Clyde
ENIGMA consortium: et al., Left-right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case-control study of structural brain asymmetries in schizophrenia, with MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case-control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case-control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case-control status. Subtle case-control differences of brain macrostructural asymmetry may reflect differences at the molecular, cytoarchitectonic, or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia., The ENIGMA project is in part supported by the National Institute of Biomedical Imaging and Bioengineering of the NIH (U54EB020403). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Individual Funding Sources: D.S., M.C.P., S.E.F., and C.F.: Max Planck Society (Germany). R.A.-A.: Miguel Servet contract from the Carlos III Health Institute (CP18/00003). J.V.-B.: Instituto de Investigación Sanitaria Valdecilla (IDIVAL) (INT/A21/10, INT/A20/04). D.A.: South-Eastern Norway Regional Health Authority (2019107, 2020086). L.T.W.: Research Council of Norway (223273, 300767), South-Eastern Norway Regional Health Authority (2019101), and European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (ERC StG, 802998). O.A.A.: Research Council of Norway (223273, 275054), KG Jebsen Stiftelsen, South East Norway Health Authority (2017-112, 2019-108). P.K.: NIH (R01MH123163, R01EB015611). M.J.G.: National Health and Medical Research Council (NHMRC) (630471, 1051672, 1081603). C.P.: NHMRC Senior Principal Research Fellowship (1105825), NHMRC L3 Investigator Grant (1196508). V.D.C.: NIH (R01MH118695), NSF (2112455). J.M.F.: Senior Research Career Scientist Award, Department of Veterans Affairs. P.F.-C.: Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III, cofunded by European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF), “Investing in your future”): Sara Borrell Research contract (CD19/00149). G.S.: Italian Ministry of Health (RC17-18-19-20-21/A). A.N.V.: National Institute of Mental Health (NIMH), Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, University of Toronto. Y.-C.C.: Korean Mental Health Technology R&D Project (HL19C0015) and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI18C2383), funded by the Ministry of Health & Welfare, Republic of Korea. J.M.S.: NIH (1P20RR021938-01). A.R.M.: NIH (P30GM122734, R01MH101512). C.M.D.-C.: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024). S. Cervenka: Swedish Research Council (523-2014-3467). M. Kirschner: Swiss National Science Foundation (SNSF) (P2SKP3_178175). T.H.: CIHR (142255), Ministry of Health of the Czech Republic (16-32791A, NU20-04-00393), Brain & Behavior Research Foundation (BBRF) Young and Independent Investigator Awards. A. James: Medical Research Council (MRC) (G0500092). P.H.: NARSAD grant from the BBRF (28445), Research Grant from the Novartis Foundation (20A058). R.C.G.: NIH (1R01MH117014, 1R01MH119219). N.J.: NIH (R01MH117601). S.E.M.: NHMRC (APP1172917). J.A.T.: NIH (R01MH1​21246). Dataset-Specific Funding Sources and Acknowledgments: AMC: Supported by grants from The Netherlands Organisation for Health Research and Development (ZonMw) (3160007, 91676084, 31160003, 31180002, 31000056, 2812412, 100001002, 100002034), the Dutch Research Council (NWO) (90461193, 40007080, 48004004, 40003330), the Amsterdam Brain Imaging Platform, Neuroscience Campus Amsterdam, and the Dutch Brain Foundation. Processing with FreeSurfer was performed on the Dutch e-Science Grid through BiG Grid project and COMMIT project “e-Biobanking with imaging for healthcare,” which are funded by the NWO. ASRB: Australian Schizophrenia Research Bank, supported by the NHMRC (Enabling Grant, 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. Chief Investigators for ASRB were S.V.C., P.T.M., B.J.M., U.S., R.J.S., V.J.C., F.A.H., C.P., Assen Jablensky. We thank C.M.L., the ASRB Manager, and acknowledge the help of Jason Bridge for ASRB database queries. CAMH: Datasets were collected and shared with support from the CAMH Foundation and the CIHR. CASSI (Cognitive and Affective Symptoms in Schizophrenia Intervention): Supported by the University of New South Wales School of Psychiatry, the NHMRC (568807), Neuroscience Research Australia, the Schizophrenia Research Institute utilizing infrastructure funding from NSW Ministry of Health, the Macquarie Group Foundation, and the ASRB (see above). CIAM (Cortical Inhibition and Attentional Modulation): The CIAM group (PI: F.M.H.) was supported by the University Research Committee, University of Cape Town; South African National Research Foundation (NRF); South African Medical Research Council (SA MRC). CLING (Clinical Neuroscience Goettingen): Sample data collection partially supported by the Deutsche Forschungsgemeinschaft (DFG) (GR1950/5-1 to O.G.). COBRE (Center for Biomedical Research Excellence): Supported by NIH (R01EB006841, P20GM103472, 5R01MH094524 to V.D.C. and J.A.T. R01AA021771 and P50AA022534 to J.M.S.), and the NSF (1539067). EdinburghEHRS: Funded by the MRC (G9226254, G9825423), the Dr. Mortimer and Theresa Sackler Foundation. EdinburghFunc: Funded by the MRC Clinical Training Fellowship (G84/5699) and Health Foundation Clinician Scientist Fellowship (2268/4295). EdinburghSFMH: Funded by an award from the Translational Medicine Research Collaboration (NS_EU_166), Scottish Enterprise, Pfizer, the Dr. Mortimer and Theresa Sackler Foundation. The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336. Is e buidheann carthannais a th’ ann an Oilthigh Dhùn Èideann, clàraichte an Alba, àireamh clàraidh SC005336. EONCKS: Supported by the SA MRC and the New Partnership for Africa’s Development initiative through the Department of Science and Technology of South Africa (#65174). ESO: Supported by the Ministry of Health of the Czech Republic (NU20-04-00393). FBIRN (Function Biomedical Informatics Research Network): Supported by the National Center for Research Resources at the NIH (1 U24 RR021992 (FBIRN) and 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org)). Data were processed by the UCI High-Performance Computing cluster supported by Joseph Farran (supported by NIMH R01 MH-58262), Harry Mangalam, and Adam Brenner (supported by NIH 5R01 MH61603, 2R01MH058251), and the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH (through grant UL1 TR000153). FBIRN thank Mrs. Liv McMillan for overall study coordination. FOR2107 Marburg: Funded by the DFG, T.T.J.K. (speaker FOR2107; KI588/14-1, KI588/14-2), Axel Krug (KR3822/5-1, KR3822/7-2), I.N. (NE2254/1-2, NE2254/3-1, NE2254/4-1), Carsten Konrad (KO4291/3-1), and A. Jansen (JA1890/7-1, JA1890/7-2). FOR2107 Münster: Funded by the DFG (FOR2107 DA1151/5-1, DA1151/5-2 to U.D.; SFB-TRR58, Projects C09 and Z02 to U.D.) and the Interdisciplinary Center for Clinical Research of the medical faculty of Münster (Dan3/012/17 to U.D.). Frankfurt: MRI was performed at the Frankfurt Brain Imaging Centre, supported by the DFG and the German Ministry for Education and Research (Brain Imaging Center Frankfurt/Main, DLR01GO0203). GAP (Genetics and Psychosis): The GAP dataset represents independent research funded by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London, Maudsley National Health Service (NHS) Foundation Trust, and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. GIPSI: Supported by “PRISMA U.T” Colciencias Invitación 990 del 3 de Agosto de 2017, Código 111577757629, Contrato 781 de 2017. GROUP: We thank Truda Driesen and Inge Crolla for their coordinating roles in the data collection, as well as the G.R.O.U.P. investigators: R.S.K., Don H. Linszen, Jim van Os, Durk Wiersma, Richard Bruggeman, W.C., L.dH., Lydia Krabbendam, Inez Myin-Germeys. Infrastructure for the GROUP study is funded through the Geestkracht programme of ZonMw (10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord; Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center, The Hague; Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem; Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal, and Delta). HMS (Homburg Multidiagnosis Study): Sample data collection was supported by a grant of the Competence Network Schizophrenia to O.G. HUBIN (Human Brain Informatics): Supported by the Swedish Research Council (K2015-62X-15077-12-3), 2017-00949, the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation. Huilong: Funded by the National Natural Science Foundation of China (81761128021; 31671145; 81401115; 81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016), Beijing Natural Science Foundation (7162087), Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: Imaging Genetics in Psychosis study, funded by Project Grants from the NHMRC (APP630471 and APP1081603), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). This project used participants from the ASRB (see above), using an infrastructure grant from the NSW Ministry of Health. IMH: Supported by research grants from the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP C009/2006) awarded to K.S. KaSP: Supported by the Swedish Research Council (K2015-62X-15077-12-3), and by grants from the Swedish Medical Research Council (2009-7053, 2013-2838, 523-2014-3467), the Swedish Brain Foundation, Åhlén-siftelsen, Svenska Läkaresällskapet, Petrus och Augusta Hedlunds Stiftelse, Torsten Söderbergs Stiftelse, the AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science, Söderbergs Königska Stiftelse, Professor Bror Gadelius Minne, Knut och Alice Wallenbergs stiftelse, the Swedish Federal Government under the LUA/ALF agreement (C.M.S., S. Cervenka), Centre for Psychiatry Research, KID-funding from the Karolinska Institutet. Madrid: Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), cofinanced by ERDF Funds from the European Commission, “A way of making Europe,” CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program (FP7-4-HEALTH-2009-2.2.1-2-241909—Project EU-GEI, FP7-HEALTH-2013-2.2.1-2-603196—Project PSYSCAN, and FP7-HEALTH-2013-2.2.1-2-602478—Project METSY), European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (115916—Project PRISM, and 777394—Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz. MCIC: Supported by the NIH (NIH/NCRR P41RR14075, R01EB005846 to V.D.C.), the Department of Energy (DE-FG02- 99ER62764), the Mind Research Network, the Morphometry BIRN (1U24, RR021382A), the Function BIRN (U24RR021992-01, NIH.NCRR MO1 RR025758-01, NIMH 1RC1MH089257 to V.D.C.), the DFG (research fellowship to S.E.), and a NARSAD Young Investigator Award (to S.E.). MPRC: Support received from NIH (U01MH108148, 2R01EB015611, R01MH112180, R01DA027680, R01MH085646, P50MH103222, and T32MH067533), a State of Maryland contract (M00B6400091), and NSF grant (1620457). OLIN: Supported by NIH (R01MH106324, R01MH077945). Osaka: Partially supported by AMED (JP21dm0307002, JP21dm0207069, JP21dk0307103, JP21uk1024002, and JP21wm0425012), JSPS KAKENHI (JP20H03611, JP20K06920), and Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders of NCNP. Computations were performed using Research Center for Computational Science, Okazaki, Japan. Oxford: We would like to thank the participants and their families, referring psychiatrists, and the Donnington Health Centre, Oxford. This study is supported by the MRC, OHSRC, UK EPSRC, BBSRC, and Wellcome Trust. PAFIP: We wish to thank all PAFIP research teams and all patients and family members who participated in the study. PAFIP has been funded by Instituto de Salud Carlos III through the projects PI14/00639, PI14/00918, and PI17/01056 (cofunded by ERDF/ESF “Investing in your future”), Health Research Institute Marques de Valdecilla (NTC0235832, NCT02534363), Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499, PI060507, PI10/00183, the SENY Fundació Research Grant (CI 2005‐0308007), the Fundación Marqués de Valdecilla (API07/011), MINECOSAF2013-46292-R, PSYSCAN (Exp.: HEALTH.2013.2.2.1-2_Grant agreement no. 603196). We want to particularly acknowledge the patients and the BioBankValdecilla (PT13/0010/0024) integrated in the Spanish National Biobanks Network for its collaboration. We thank IDIVAL Neuroimaging Unit for its help in the technical execution of this work. RSCZ: Supported in part by the RFBR (20-013-00748). SCORE: This study was supported in part by the SNSF (3232BO_119382). We thank the FePsy (Frueherkennung von Psychosen; early detection of psychosis) Study Group from the University of Basel, Department of Psychiatry, Switzerland, for the recruitment of the study participants. The FePsy Study was supported in part by grant no. SNF 3200-057216/1, ext./2, ext./3. SNUH: Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and the Korea Brain Research Institute (KBRI) basic research program through the KBRI, funded by the Ministry of Science, ICT & Future Planning (2019R1C1C1002457, 2020M3E5D9079910, 21-BR-03–01). SWIFT: Supported in part by the SNSF (320030_146789). TOP: Supported by the Research Council of Norway (#160181, 190311, 223273, 213837, 249711), the South-East Norway Health Authority (2014114, 2014097, 2017- 112), the Kristian Gerhard Jebsen Stiftelsen (SKGJ‐MED‐008), and the European Community’s Seventh Framework Programme (FP7/2007–2013), grant agreement no. 602450 (IMAGEMEND). UCISZ: Supported by the NIMH (R21MH097196 to T.G.M.v.E.). Data were processed by the UCI High-Performance Computing cluster (see FBIRN). UMCU: Supported by ZonMw (90802123, 91746370 to H.E.H.P., and 10-000-1001 to R.S.K.). UNIBA: Supported by grant funding from the Italian Ministry of Research (2017M7SZM8_004, PI A.B.; 2017K2NEF4, PI G.P.). UNIMAAS: Supported by ZonMw (91112002) and by a personal grant to T.v.A. (ZonMw-VIDI: 91712394). This clinical trial was registered in the Dutch clinical trial registry under ID: NTR5094 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR5094). Zurich: Funded by the SNSF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Accelerated Cortical Thinning in Schizophrenia Is Associated With Rare and Common Predisposing Variation to Schizophrenia and Neurodevelopmental Disorders

  • González-Peñas, Javier
  • Alloza, Clara
  • Brouwer, Rachel
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • González-Lois, Noemí
  • Gallego, Ana Guil
  • Hoyos, Lucía de
  • Gurriarán, Xaquín
  • Andreu-Bernabeu, Álvaro
  • Romero-García, Rafael
  • Fañanás, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Arrojo, Manuel
  • Vilella, Elisabet
  • Gutiérrez-Zotes, Alfonso
  • Perez-Rando, Marta
  • Moltó, María Dolores
  • Buimer, Elizabeth
  • van Haren, Neeltje
  • Cahn, Wiepke
  • O'Donovan, Michael
  • Kahn, René S
  • Arango, Celso
  • Pol, Hilleke Hulshoff
  • Janssen, Joost
  • Schnack, Hugo
Schizophrenia is a highly heritable disorder characterized by increased cortical thinning throughout the life span. Studies have reported a shared genetic basis between schizophrenia and cortical thickness. However, no genes whose expression is related to abnormal cortical thinning in schizophrenia have been identified., This work was supported by Spanish Ministry of Science, Innovation and Universities Instituto de Salud Carlos III (Grant Nos. SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, and PI20/00721), cofinanced by European Regional Development Funds from the European Commission, “A way of making Europe,” CIBERSAM (Centro de Investigación Biomédica en Red de Salud Menta); Madrid Regional Government (Grant No. B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; the European Union Seventh Framework Program (Grant Nos. FP7-4-HEALTH-2009-2.2.1-2-241909 [Project EU-GEI], FP7- HEALTH-2013-2.2.1-2-603196 [Project PSYSCAN], and FP7-HEALTH-2013-2.2.1-2-602478 [Project METSY]); and the European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 115916, Project PRISM, and Grant No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. CMD-C holds a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (Grant No. JR19/00024). JG-P held a Sara Borrell grant during the development of the research from Instituto de Salud Carlos III (Grant No. CD20/00118)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

  • Sønderby, Ida E.
  • Ching, Christopher R. K.
  • Thomopoulos, Sophia I.
  • Meer, Dennis van der
  • Sun, Daqiang
  • Villalón-Reina, Julio E.
  • Agartz, Ingrid
  • Amunts, Katrin
  • Arango, Celso
  • Armstrong, Nicola J.
  • Ayesa-Arriola, Rosa
  • Bakker, Geor
  • Bassett, Anne S.
  • Boomsma, Dorret I.
  • Bülow, Robin
  • Butcher, Nancy J.
  • Calhoun, Vince D.
  • Caspers, Svenja
  • Chow, Eva W C
  • Cichon, Sven
  • Ciufolini, Simone
  • Craig, Michael C.
  • Crespo-Facorro, Benedicto
  • Cunningham, Adam C.
  • Dale, Anders M.
  • Dazzan, Paola
  • de Zubicaray, Greig I.
  • Djurovic, Srdjan
  • Doherty, Joanne L.
  • Donohoe, Gary
  • Draganski, Bogdan
  • Durdle, Courtney A.
  • Ehrlich, Stefan
  • Emanuel, Beverly S.
  • Espeseth, Thomas
  • Fisher, Simon E.
  • Ge, Tian
  • Glahn, David C.
  • Grabe, Hans J.
  • Gur, Raquel E.
  • Gutman, Boris A.
  • Haavik, Jan
  • Håberg, Asta K.
  • Hansen, Laura A.
  • Hashimoto, Ryota
  • Hibar, Derrek P.
  • Holmes, Avram J.
  • Hottenga, Jouke-Jan
  • Hulshoff Pol, Hilleke E
  • Jalbrzikowski, Maria
  • Knowles, Emma E. M.
  • Kushan, Leila
  • Linden, David E J.
  • Liu, Jingyu
  • Lundervold, Astri J.
  • Martin-Brevet, Sandra
  • Martínez, Kenia
  • Mather, Karen A.
  • Mathias, Samuel R.
  • McDonald-McGinn, Donna M.
  • McRae, Allan F.
  • Medland, Sarah E.
  • Moberget, Torgeir
  • Modenato, Claudia
  • Monereo Sánchez, Jennifer
  • Moreau, Clara A.
  • Mühleisen, Thomas W.
  • Paus, Tomas
  • Pausova, Zdenka
  • Prieto, Carlos
  • Ragothaman, Anjanibhargavi
  • Reinbold, Céline S.
  • Reis Marques, Tiago
  • Repetto, Gabriela M.
  • Reymond, Alexandre
  • Roalf, David R.
  • Rodriguez-Herreros, Borja
  • Rucker, James J.
  • Sachdev, Perminder S.
  • Schmitt, James E.
  • Schofield, Peter R.
  • Silva, Ana I.
  • Stefansson, Hreinn
  • Stein, Dan J.
  • Tamnes, Christian K.
  • Tordesillas-Gutiérrez, Diana
  • Ulfarsson, Magnus O.
  • Vajdi, Ariana
  • van 't Ent, Dennis
  • Bree, Marianne B. M. van den
  • Vassos, Evangelos
  • Vázquez-Bourgon, Javier
  • Vila-Rodriguez, Fidel
  • Walters, G Bragi
  • Wen, Wei
  • Westlye, Lars T.
  • Wittfeld, Katharina
  • Zackai, Elaine H.
  • Stefánsson, Kári
  • Jacquemont, Sebastien
  • Thompson, Paul M.
  • Bearden, Carrie E.
  • Andreassen, Ole A.
  • ENIGMA-CNV Working Group
  • ENIGMA 22q11.2 Deletion Syndrome Additional
Data sharing is not applicable to this article as no new data were created or analyzed in this study., ENIGMA-CNV Additional Members: Manon Bernard, Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. Nicholas B. Blackburn, Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA; South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA. Rune Bøen, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway. Eco de Geus, Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Amsterdam Public Health (APH) Research Institute, Amsterdam UMC, Amsterdam, The Netherlands. Sonja M. C. de Zwarte, Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Marta Di Forti, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Oleksandr Frei, Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health; Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway and Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway, Vincent Frouin, Université Paris-Saclay, CEA, Neurospin, Gif-sur-Yvette, France. Masaki Fukunaga, Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Japan. Jayne Y. Hehir-Kwa, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Manon H. J. Hillegers, Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center, Rotterdam, The Netherlands. Per Hoffmann, Institute of Human Genetics, University of Bonn, Bonn, Germany; Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland. Georg Homuth, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. Neda Jahanshad, Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA. Sanne Koops, Department of Biomedical Sciences of Cells & Systems, Cognitive Neurosciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands. Kuldeep Kumar, Sainte Justine Research Center, University of Montreal, Montreal, QC, Canada. Masataka Kikuchi, Graduate School of Medicine, Osaka University, Osaka, Japan. Stephanie Le Hellard, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Costin Leu, Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Stanley Center for Psychiatric Research, Broad Institute of Harvard and M.I.T, Cambridge, MA, USA. Robin M Murray, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Terje Nærland, KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway; NevSom, Department of Rare Disorders, Oslo University Hospital, Oslo, Norway. Lars Nyberg, Integrative Medical Biology (IMB) Umeå University, Umeå, Sweden; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. Roel A. Ophoff, Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. G Bruce Pike, Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. Sigrid B. Sando, Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway. Jean Shin, The Hospital for Sick Children, Toronto, ON, Canada; Departments of Physiology and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada. Elena Shumskaya, Donders Institute for Brain, Cognition, and Behavior, Nijmegen, The Netherlands. Sanjay M. Sisodiya, Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Chalfont Centre for Epilepsy, Chalfont-St-Peter, Bucks, UK. Vidar M. Steen, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Alexander Teumer, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, Anne Uhlmann, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Margaret J. Wright, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia, ENIGMA 22q11.2 Deletion Syndrome Additional Members: Kevin M. Antshel, Department of Psychology, Syracuse University, Syracuse, NY, USA. Linda E. Campbell, University of Newcastle, Newcastle, NSW, Australia. Nicolas A. Crossley, Department of Psychiatry, Pontificia Universidad Católica de Chile, Santiago, Chile. T. Blaine Crowley, Division of Human Genetics and 22q and You Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Eileen Daly, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Ania M. Fiksinski, Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada; Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, ON, Canada; Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Jennifer K. Forsyth, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA. Wanda Fremont, Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. Naomi J. Goodrich-Hunsaker, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA; Department of Neurology, University of Utah, Salt Lake City, UT, USA. Maria Gudbrandsen, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Rachel K. Jonas, Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences and Psychology, University of California Los Angeles, Los Angeles, CA, USA. Wendy R. Kates, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA. Amy Lin, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA. Kathryn L. McCabe, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA; Department of Psychology, University of Newcastle, Newcastle, NSW, Australia. Hayley Moss, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Declan G. Murphy, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK; Behavioural Genetics Clinic, Adult Autism Service, Behavioural and Developmental Psychiatry Clinical Academic Group, South London and Maudsley NHS Foundation Trust, London, UK. Kieran C. Murphy, Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. Michael J. Owen, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Kosha Ruparel, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Tony. J. Simon, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA. Therese van Amelsvoort, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands. Jacob A. S. Vorstman, Department of Psychiatry, The Hospital for Sick Children, Toronto, ON, Canada., The Enhancing NeuroImaging Genetics through Meta-Analysis copy number variant (ENIGMA-CNV) and 22q11.2 Deletion Syndrome Working Groups (22q-ENIGMA WGs) were created to gain insight into the involvement of genetic factors in human brain development and related cognitive, psychiatric and behavioral manifestations. To that end, the ENIGMA-CNV WG has collated CNV and magnetic resonance imaging (MRI) data from ~49,000 individuals across 38 global research sites, yielding one of the largest studies to date on the effects of CNVs on brain structures in the general population. The 22q-ENIGMA WG includes 12 international research centers that assessed over 533 individuals with a confirmed 22q11.2 deletion syndrome, 40 with 22q11.2 duplications, and 333 typically developing controls, creating the largest-ever 22q11.2 CNV neuroimaging data set. In this review, we outline the ENIGMA infrastructure and procedures for multi-site analysis of CNVs and MRI data. So far, ENIGMA has identified effects of the 22q11.2, 16p11.2 distal, 15q11.2, and 1q21.1 distal CNVs on subcortical and cortical brain structures. Each CNV is associated with differences in cognitive, neurodevelopmental and neuropsychiatric traits, with characteristic patterns of brain structural abnormalities. Evidence of gene-dosage effects on distinct brain regions also emerged, providing further insight into genotype–phenotype relationships. Taken together, these results offer a more comprehensive picture of molecular mechanisms involved in typical and atypical brain development. This “genotype-first” approach also contributes to our understanding of the etiopathogenesis of brain disorders. Finally, we outline future directions to better understand effects of CNVs on brain structure and behavior., The ENIGMA Consortium is supported by the NIH Big Data to Knowledge (BD2K) program under consortium grant number U54 EB020403 (PI: Thompson). OAA is supported by the Research Council of Norway, South East Norway Health Authority, KG Jebsen Stiftelsen, EU H2020. C. A. has been funded by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241,909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603,196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602,478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative two Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. R. A-A is funded by a Miguel Servet contract from the Carlos III Health Institute (CP18/00003). G. B. is supported by the Dutch Organization for Health Research and Development ZonMw (grants 91112002 & 91712394). A. S. B. is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, Canadian Institutes of Health Research (CIHR) grants MOP-79518, MOP-89066, MOP-97800 and MOP-111238, and NIMH grant number U01 MH101723–01(3/5). C. E. B. is also supported by the National Institute of Mental Health: RO1 MH085953, R01 MH100900 and 1U01MH119736. N. E. B. is granted the KNAW Academy Professor Award (PAH/6635). V. D. C. is supported by NIH R01 MH094524. S. C. is supported by the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3); Helmholtz Initiative and Networking Fund. C. R. K. C. is supported by NIA T32AG058507. E. W. C. C. is supported by the Canadian Institutes of Health Research, Ontario Mental Health Foundation grant MOP-74631 and NIMH grant U01MH101723–01(3/5). S. Ci. has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3). M. C. C. is supported by the Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. N. A. C. is supported by Agencia Nacional de Investigación y Desarrollo (ANID Chile) PIA ACT192064. GId. Z. is supported by the NHMRC. J. L. D. and D. E. J. L. are supported by the Wellcome Trust. T. B. C. is supported by NICHD grant PO1-HD070454, NIH grant UO1-MH191719, and NIMH grant R01 MH087636-01A1. AMD is supported by U24DA041147. B. D. is supported by the Swiss National Science Foundation (NCCR Synapsy, project grant numbers 32003B_135679, 32003B_159780, 324730_192755 and CRSK-3_190185), the Leenaards Foundation and the Roger De Spoelberch Foundation. SE is supported by the NARSAD-Young Investigator Grant “Epigenetic Regulation of Intermediate Phenotypes in Schizophrenia”. B. E. S. is supported by the NIH (NIMH). D. C. G. is supported by NIH grant numbers MH078143, MH083824, AG058464. W. R. K. is supported by NIH/MH R0106824. R. E. G. is supported by NIH/NIMH grant numbers MH087626, MH119737. DMMcD-McG is supported by National Institutes of Mental Health (NIMH), grant numbers MH119737-02; MH191719; and MH087636-01A1. S. E. M. is supported by NHMRC grants APP1103623; APP1158127; APP1172917. TM is supported by Research Council of Norway - grant number 273345. D. G. M. is supported by the National Institute for Health Research Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and EU-AIMS (European Autism Interventions)/EU AIMS-2-TRIALS, a European Innovative Medicines Initiative Joint Undertaking under grant agreements 115300 and 777394. T. N. was supported by Stiftelsen KG Jebsen under grant number SKGJ-MED-021. R. A. O. is supported by NIMH R01 MH090553. S. Y. S. has been funded by the Canadain Institutes of Health Research. M. J. O. is supported by MRC Centre grant MR/L010305/1 and Wellcome Trust grant 100,202/Z/12/Z; Dr. Owen has received research support from Takeda. Z. P. is supported by CIHR, CFI, HSFC. B. G. P. is supported by CIHR FDN 143290 and CAIP Chair. G. M. R. is supported by Fondecyt-Chile #1171014 and ANID-Chile ACT192064. A. Re. was supported by a grant from the Swiss National Science Foundation (31003A_182632). DRR is supported by R01 MH120174 (PI: Roalf). This report represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (to J. J. R). PSS is supported by NHMRC (Australia) program grant 1093083. J. E. S. is supported by NIH K01-ES026840. S. M. S. is supported by the Epilepsy Society. T. J. S. is supported by NIH grants R01MH107108, R01HD042794, and HDU54079125. I. E. S. is supported by South-Eastern Norway Regional Health Authority (#2020060), European Union's Horizon2020 Research and Innovation Programme (CoMorMent project; grant #847776) and the KG Jebsen Foundation (SKGJ-MED-021). V. M. S. is supported by Research Council of Norway (CoE funding scheme, grant number 223273). D. J. S. is supported by the SA MRC. C. K. T. is supported by Research Council of Norway (#230345, #288083, #223273) and South-Eastern Norway Regional Health Authority (#2019069, #2021070, #500189). D. T.-G. was supported by the Instituto de Salud Carlos III (PI14/00639 and PI14/00918) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). Dvd. M. is supported by Research Council of Norway #276082. F. V. R. is supported by the Michael Smith Foundation for Health Research Scholar Award. deCODE genetics has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreements' no. 115008 (NEWMEDS) and no. 115300 (EUAIMS), of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (EU-FP7/2007–2013). L. T. W. is supported by Research Council of Norway, European Research Council. The IDIVAL neuroimage unit is supported by Instituto de Salud Carlos III PI020499, research funding SCIII-INT13/0014, MICINN research funding SAF2010-20840-C02-02, SAF2013-46292-R. The TOP/NORMENT study are supported by the Research Council of Norway (#223273). The GOBS study data collection was supported in part by the National Institutes of Health (NIH) grants: R01 MH078143, R01 MH078111, and R01 MH083824 with work conducted in part in facilities constructed under the support of NIH grant number C06 RR020547. The Sydney Memory and Ageing Study has been funded by three National Health & Medical Research Council (NHMRC) Program Grants (ID No. ID350833, ID568969, and APP1093083). We thank the participants and their informants for their time and generosity in contributing to this research. We also acknowledge the MAS research team: https://cheba.unsw.edu.au/research-projects/sydney-memory-and-ageing-study. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. The OATS study has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Aging Well, Aging Productively Program (ID No. 401162); NHMRC Project (seed) Grants (ID No. 1024224 and 1025243); NHMRC Project Grants (ID No. 1045325 and 1085606); and NHMRC Program Grants (ID No. 568969 and 1093083). We thank the participants for their time and generosity in contributing to this research. This research was facilitated through access to Twins Research Australia, a national resource supported by a Centre of Research Excellence Grant (ID No. 1079102) from the National Health and Medical Research Council. The NCNG sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the KG Jebsen Foundation, the Research Council of Norway, to S. L. H., V. M. S., A. J. L., and T. E. The authors thank Dr. Eike Wehling for recruiting participants in Bergen, and Professor Jonn-Terje Geitung and Haraldplass Deaconess Hospital for access to the MRI facility. Additional support by RCN grants 177458/V50 and 231286/F20. The Betula study was supported by a Wallenberg Scholar Grant (KAW). The HUNT Study is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU—Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI. Research for the GAP cohort was supported by the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Center for Mental Health award to South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London, London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. S.J. is supported by Calcul Quebec (http://www.calculquebec.ca), Compute Canada (http://www.computecanada.ca), the Brain Canada Multi investigator research initiative (MIRI), the Institute of Data Valorization (Canada First Research Excellence Fund), CHIR, Canada Research Chairs and the Jeanne et Jean Louis Levesque Foundation. The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO), MW904-61-193 (de Geus & Boomsma), MaGWnr: 400-07-080 (van 't Ent), MagW 480-04-004 (Boomsma), NWO/SPI 56-464-14,192 (Boomsma), the European Research Council, ERC-230374 (Boomsma), and Amsterdam Neuroscience. Funding for genotyping was obtained from the National Institutes of Health (NIMH U24 MH068457-06; Grand Opportunity grants 1RC2 MH089951, and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. The Brainscale study was supported by the Netherlands Organization for Scientific Research MagW 480-04-004 (Boomsma), 51.02.060 (Hilleke Hulshoff Pol), 668.772 (Boomsma & Hulshoff Pol); NWO/SPI 56-464-14192 (Boomsma), the European Research Council (ERC230374) (Boomsma), High Potential Grant Utrecht University (Hulshoff Pol), NWO Brain and Cognition 433-09-220 (Hulshoff Pol). SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide SNP typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The ENIGMA-22q11.2 Deletion Syndrome Working Group wishes to acknowledge our dear colleague Dr. Clodagh Murphy, who sadly passed away in April 2020. Open access funding enabled and organized by Projekt DEAL., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, A.
  • González-Ortega, I.
  • Alberich, S.
  • De Azúa, S.R.
  • Bernardo, M.
  • Bioque, M.
  • Cabrera, B.
  • Corripio, I.
  • Arango, C.
  • Lobo, A.
  • Sánchez-Torres, A.M.
  • Cuesta, M.J.
  • Ugarte, A.
  • Fernández, M.
  • Mezquida, G.
  • Meseguer, A.
  • Vieta, E.
  • Torrent, C.
  • Contreras, F.
  • Albacete, A.
  • Alonso-Solís, A.
  • Rabella, M.
  • Moreno-Izco, L.
  • Usall, J.
  • Butjosa, A.
  • Ibáñez, Á.
  • Bobes, J.
  • Al-Halabí, S.
  • Zapata-Usábel, M.T.
  • Laporta-Herrero, I.
  • Balanzá-Martínez, V.
  • Bergé, D.
  • Mané, A.
  • Rodriguez-Jimenez, R.
  • Morales-Muñoz, I.
  • Gutierrez, M.
  • Zabala, A.
  • Sarró, S.
  • Landin-Romero, R.
  • Serna, De La
  • Baeza, I.
  • Parellada, M.
  • Espliego, A.
  • Juan, J.S.
  • Aguilar, E.
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

La psiquiatría post-COVID-19

  • Vieta, Eduard
  • Pérez Solà, Víctor
  • Arango, Celso
EV would like to thank the Ministry of Science and Research (PI15/00283, PI18/00805) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), the Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 1365), and project SLT006/17/00357 of the Strategic Plan for Health Research and Innovation (PERIS) 2016–2020 (Department of Health), CERCA PROGRAM, Government of Catalonia. VP would like to thank the Ministry of Science and Research (PI19/00236) integrated in the National R+D+I Plan and co-financed by the ISCIII-General Subdirectorate of Evaluation and the European Regional Development Fund (ERDF), CIBERSAM G21. Commission for Universities and Research, Department of Innovation, Universities, and Business (DIUE), Government of Catalonia (2017 SGR 134), CERCA Program, Government of Catalonia. CA has received support from the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by the European Commission's ERDF Fund, “A way of making Europe,” CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 115916, Project PRISM, and grant agreement No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, and Fundación Alicia Koplowitz.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets

  • Postema, Merel C.
  • van Rooij, Daan
  • Anagnostou, Evdokia
  • Arango, Celso
  • Auzias, Guillaume
  • Behrmann, Marlene
  • Filho, Geraldo Busatto
  • Calderoni, Sara
  • Calvo Escalona, Rosa
  • Daly, Eileen
  • Deruelle, Christine
  • Di Martino, Adriana
  • Dinstein, Illan
  • Duran, Fabio Luis S.
  • Durston, Sarah
  • Ecker, Christine
  • Ehrlich, Stefan
  • Fair, Damien
  • Fedor, Jennifer
  • Feng, Xin
  • FitzGerald, Jackie
  • Floris, Dorothea L.
  • Freitag, Christine M.
  • Gallagher, Louise
  • Glahn, David C.
  • Gori, Ilaria
  • Haar, Shlomi
  • Hoekstra, Liesbeth
  • Jahanshad, Neda
  • Jalbrzikowski, Maria
  • Janssen, Joost
  • King, Joseph A.
  • Kong, Xiang-Zhen
  • Lázaro García, Luisa
  • Lerch, Jason P.
  • Luna, Beatriz
  • Martinho, Mauricio M.
  • McGrath, Jane
  • Medland, Sarah E.
  • Muratori, Filippo
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, Ana
  • González Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo Arroyo, Miquel
  • Bioque Alcázar, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez-Torres, Ana M.
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psycho- sis sample, when stratifying the interaction by cannabis use and familial or non-familial psy- chosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family his- tory of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no fam- ily history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • De Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás Saura, Lourdes
  • Bobes García, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, M. Dolors
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango López, Celso
  • González-Peñas, Javier
Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N = 3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina García, Mariola
  • Fraguas, David
  • Del Rey Mejias, Angel
  • Mezquida Mateos, Gisela
  • Sánchez-Torres, Ana M.
  • Amoretti Guadall, Silvia
  • Lobo, Antonio
  • González-Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta i Pascual, Eduard, 1963-
  • Baeza, Inmaculada, 1970-
  • Mané Santacana, Anna
  • Cuesta, Manuel J.
  • Serna Gómez, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo Arroyo, Miquel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History

  • González-Pinto, Ana|||0000-0002-2568-5179
  • González-Ortega, Itxaso|||0000-0001-7074-4353
  • Alberich, Susana|||0000-0002-4945-3428
  • Ruiz de Azúa, Sonia
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Bioque, Miquel|||0000-0001-6887-7149
  • Cabrera, Bibiana|||0000-0002-7749-5449
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Arango, Celso|||0000-0003-3382-4754
  • Lobo, Antonio|||0000-0002-9098-655X
  • Sánchez Torres, Ana Maria|||0000-0002-9505-2406
  • Cuesta, Manuel J.|||0000-0003-0250-5718
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Recent natural selection conferred protection against schizophrenia by non-antagonistic pleiotropy

  • González Peñas, J.
  • Hoyos, Lucía de
  • Díaz Caneja, C. M.
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. J González-Peñas holds a Sara Borrel from Instituto de Salud Carlos III (CD20/00118). C. M. Díaz-Caneja holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024)
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu Bernabeu, Á.
  • Díaz Caneja, C. M.
  • Costas, J.
  • De Hoyos, L.
  • Stella, C.
  • Gurriarán, X.
  • Alloza, C.
  • Fañanás, L.
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), and FP7- HEALTH-2013-2.2.1-2- 602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. We are grateful to Paloma Pantoja for her assistance in the design of the figures. A.A.-B. holds a Rio Hortega Grant from Instituto de Salud Carlos III (CM20/00114). C.M.D.-C. holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024)., Andreu-Bernabeu, Á., Díaz-Caneja, C.M., Costas, J., De Hoyos, L., Stella, C., Gurriarán, X., Alloza, C., Fañanás, L., Bobes, J., González-Pinto, A., Crespo-Facorro, B., Martorell, L., Vilella, E., Muntané, G., Nacher, J., Molto, M.D., Aguilar, E.J., Parellada, M., Arango, C., González-Peñas, J.